Baidu
map

CFDA全面接轨FDA,年底试行药品电子通用技术文档系统(eCTD)

2017-07-30 MedSci MedSci

2017年5月30日,CFDA药品审评中心的工作人员却并未休息,两部关于eCTD(药品电子技术通用技术文档)的征求意见稿选择在这一天发布,分别是《药品电子通用技术文档机构(征求意见稿)》以及《化学仿制药电子通用技术文档申报指导原则(征求意见稿)》。这也是既毕井泉局长在2月27日国务院新闻发布会上透露将建立eCTD系统并争取2017年底能够实现按新系统实行电子申报和审评以来,在推行eCTD进程方

2017年5月30日,CFDA药品审评中心的工作人员却并未休息,两部关于eCTD(药品电子技术通用技术文档)的征求意见稿选择在这一天发布,分别是《药品电子通用技术文档机构(征求意见稿)》以及《化学仿制药电子通用技术文档申报指导原则(征求意见稿)》。这也是既毕井泉局长在2月27日国务院新闻发布会上透露将建立eCTD系统并争取2017年底能够实现按新系统实行电子申报和审评以来,在推行eCTD进程方面所公布的第一个实质性举措。药审中心也表示,此举是贯彻落实国务院《关于改革药品医疗器械审评审批制度的意见》中关于eCTD的相关要求,组织信息、药学、药理毒理、临床、统计和临床药理学等专业审评人员来起草征求意见稿,社会各界有建议或修改意见可通过电子邮件进行反馈。


自2017年5月5日起,许多向美国药监局(FDA)的新药审评和研究中心(CDER)和生物药审评中心(CBER)的提交的文件,必须以eCTD提交。新药申请(NDAs),仿制药申请(ANDAs),生物制品许可申请(BLAs)和主文件(Drug Master Files, DMF)都须使用eCTD格式提交。FDA规定,DMF文件大小在10GB的提交必须使用FDA的电子提交门户 Electronic Submission Gateway(ESG)。2018年5月5日,商业调研性新药申请 (INDs) 必须使用eCTD格式递交FDA。如果CFDA在年底前试行的话,这个接轨程度是相当之快的。早在2003年,ICH已颁布eCTD指导文件,试行eCTD格式的电子申报;FDA也在2008年要求所有在美国的电子申报都必须采用eCTD格式;到了2010年,欧盟强制执行eCTD格式申报。

作为在国外已经逐步推行的药品审评中的资料提交方式,eCTD在中国的推行注定是药品注册进程中的一项关键性革命,同时也是与国际接轨的必经之路。征求意见稿的出台则让中国药审进入eCTD时代的一天变得清晰可见。

1、什么是eCTD?

所谓eCTD,即Electronic Common Technical Document的缩写,翻译为中文为“药品电子技术通用技术文档”,即药品的质量、安全和有效性方面的通用文件。这是制药企业向药物监管机构进行信息传输的一种形式,其内容需满足通用技术文件(CTD)的要求。

2003年,ICH Multi-disciplinary Group 2 (M2) 在CTD的基础上制定了eCTD的标准,eCTD可以说是电子化的CTD注册申报方式,是一个接口,用于行业与监管机构间信息的传输,以便于文件的创建、审查、生命周期管理和电子提交。相对于传统的纸质递交,eCTD电子递交更便捷、更环保。

一般而言,eCTD电子递交流程大体上可以分为三个阶段,即撰写、文档编辑与提交。申请者首先要将各类资料、数据、实验数据等进行撰写,之后由第三方专业编辑服务外包商来根据相关法规要求构建eCTD结构化文档,再由申报负责人通过事先建立好的电子传输通道,将申报文件提交至药监部门。在整个过程中,便捷、高效、规范、环保是其主要特点,因此eCTD(药品电子技术通用技术文档)因其在药品注册申报环节中的诸多优势而受到美国、日本等国家药审部门的青睐。

eCTD正成为全球药品注册申报的重要趋势,这是因为其在创建、传输、复制、审阅、检索、存档以及文件生命周期管理等方面存在诸多优势。具体而言,对于申请者来说,如一个产品在多个市场申请,则部分资料可以进行共享,大大降低成本并提高效率,对于审评者而言,eCTD资料的审阅、管理、传输以及归档十分便捷,eCTD格式同时也利于各个国家和地区的药监部门的审评意见交流。

相比较传统的纸质文件递交,eCTD格式的电子申报具有高效率、方便查看/导航、可快速溯源、实现生命周期管理、节约纸张等优势。

2003年,美国FDA开始试行eCTD,规定电子提交药品注册申请必须以eCTD的形式来进行,在FDA2015年5月发布的指南中,也明确要求ANDA、NDA、某些NDI和BLA必须以eCTD的形式提交,此指南生效后,进行完成性审核的DMF也必须以eCTD的格式来提交。欧洲EMA同样也是于2003年开始试行eCTD,并从2010年开始集中强制要求。到目前为止,除了传统的美国、日本和欧盟等ICH成员国之外,加拿大、瑞士、沙特阿拉伯、南非、澳大利亚、新西兰和泰国等国家都已经部分采纳或者正在逐步转向eCTD递交。

eCTD格式包含了CTD格式内容+模块1(见下图)。模块1的内容及要求根据申报的国家和地区各不相同,模块2~4国际通用。

图:eCTD格式内容


2、中国eCTD进行时

同国外相比,中国eCTD的进程无疑要慢许多,但随着国务院《关于改革药品医疗器械审评审批制度的意见》中明确提及eCTD以及食药监总局毕井泉局长在国务院新闻发布会上的表态,中国的eCTD进程已有了显著加速。

2017年2月7日,毕井泉局长在国务院新闻发布会上进行讲话,其中就提及要建立建立eCTD系统并争取2017年底能够实现按新系统实行电子申报和审评。这是官方第一次在公开场合提及eCTD并给出了初步时间表。

而此次CDE所出台的文件则使eCTD的进程更为清晰。征求意见的《药品电子通用技术文档结构》同国际标准一样分为五个模块,分别为:行政管理信息;总结与综述;质量资料(药学);非临床研究报告(药理毒理学);临床研究报告,对要提供信息的具体结构进行了明确划分,以帮助企业进行申报。

然而,由于编辑制作eCTD格式文件往往较为复杂,并非所有的企业都有能力与精力来完成自己产品的eCTD申报,在这种情况下,专业的第三方eCTD外包服务商便迎来了发展春天,对于一些申报产品不多的小型生产企业,或是申报数量巨大的大型跨国制药公司,这类外包公司都将是优先选择。


CTD 文件是国际公认的文件编写格式,制作一个向药品注册机构递交的结构完善的注册申请文件,共有5 个模块,模块1 是地区特异性的,模块2、3、4 和5 在各个地区是统一的。模块1 是指地区性行政信息和法规信息,包括各地区的特殊文件,例如申请表或在各地区被建议使用的标签,其内容和格式可以由每个地区的相关注册机构来指定。模块2 是指CTD文件概述和综述,由7 个部分组成,如图1 所示,是对药物质量,非临床和临床试验方面内容的高度总结概括,必须由合格的和有经验的专家来担任文件编写工作。其中“2.1”为CTD 总目录,“2.2”为申请药品的一般介绍,主要介绍药品的药理作用及临床适应证,“2.3 ~2.7”为具有资历的专家的相关综述和概要,包括:质量概要、临床前综述、临床综述、临床前研究列表总结和表格概要、临床研究概述。模块3 是指质量部分( 药学包括原料药和制剂),提供药物在化学、制剂和生物学方面的内容。模块4 是指临床前研究报告,提供原料药和制剂在毒理学、药理学及药动学试验方面的内容。模块5 是指临床研究报告,提供制剂在各项临床试验方面的内容

eCTD是以XML为骨架结构的PDF文件包,在NeeS的基础上加入了XML计算机语言,通过XML将大量的PDF文件有机结合在一起,并通过定义PDF文件的属性实现注册文件的生命周期管理。

按照eCTD 格式进行注册申报资料,既可以帮助药品研究者进一步提升行业的质量保障能力和国际竞争能力,也可以高度契合药品技术审评审批制度改革。未来随着医药企业信息化程度的提高,将eCTD 格式注册申报模式全面实施电子申报管理,不仅可以保证申报环节规范、快捷,注册资料真实完整,而且提高注册效率、节约注册成本。因此eCTD 有望成为构建药品研发和评价的新的技术平台。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1217663, encodeId=996d121e663d8, content=学习了,涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd938151921, createdName=ms1000001061862426, createdTime=Sat May 07 16:52:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029812, encodeId=09332029812e0, content=<a href='/topic/show?id=840c651286' target=_blank style='color:#2F92EE;'>#eCTD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6512, encryptionId=840c651286, topicName=eCTD)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Aug 28 21:10:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890644, encodeId=584e189064468, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sun Oct 22 19:10:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228284, encodeId=66c622828461, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 31 06:14:14 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228154, encodeId=6e492281540e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 30 19:13:24 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228152, encodeId=2883228152e2, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2emBzjO0FtqTJ05AqrEEdRmp6tmlsLXqpzfxWdtgbbgPGWRHagoK9fLTd3IayRPgkJVIVBWtdlmnkBhOIR4cFM/0, createdBy=e8d51649330, createdName=飘飘爱, createdTime=Sun Jul 30 18:44:12 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228147, encodeId=e98322814ead, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48a92091207, createdName=1571f46522m, createdTime=Sun Jul 30 17:53:48 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228134, encodeId=1b8622813468, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Jul 30 16:25:20 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2022-05-07 ms1000001061862426

    学习了,涨知识了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1217663, encodeId=996d121e663d8, content=学习了,涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd938151921, createdName=ms1000001061862426, createdTime=Sat May 07 16:52:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029812, encodeId=09332029812e0, content=<a href='/topic/show?id=840c651286' target=_blank style='color:#2F92EE;'>#eCTD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6512, encryptionId=840c651286, topicName=eCTD)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Aug 28 21:10:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890644, encodeId=584e189064468, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sun Oct 22 19:10:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228284, encodeId=66c622828461, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 31 06:14:14 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228154, encodeId=6e492281540e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 30 19:13:24 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228152, encodeId=2883228152e2, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2emBzjO0FtqTJ05AqrEEdRmp6tmlsLXqpzfxWdtgbbgPGWRHagoK9fLTd3IayRPgkJVIVBWtdlmnkBhOIR4cFM/0, createdBy=e8d51649330, createdName=飘飘爱, createdTime=Sun Jul 30 18:44:12 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228147, encodeId=e98322814ead, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48a92091207, createdName=1571f46522m, createdTime=Sun Jul 30 17:53:48 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228134, encodeId=1b8622813468, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Jul 30 16:25:20 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2017-08-28 仁心济世
  3. [GetPortalCommentsPageByObjectIdResponse(id=1217663, encodeId=996d121e663d8, content=学习了,涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd938151921, createdName=ms1000001061862426, createdTime=Sat May 07 16:52:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029812, encodeId=09332029812e0, content=<a href='/topic/show?id=840c651286' target=_blank style='color:#2F92EE;'>#eCTD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6512, encryptionId=840c651286, topicName=eCTD)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Aug 28 21:10:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890644, encodeId=584e189064468, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sun Oct 22 19:10:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228284, encodeId=66c622828461, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 31 06:14:14 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228154, encodeId=6e492281540e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 30 19:13:24 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228152, encodeId=2883228152e2, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2emBzjO0FtqTJ05AqrEEdRmp6tmlsLXqpzfxWdtgbbgPGWRHagoK9fLTd3IayRPgkJVIVBWtdlmnkBhOIR4cFM/0, createdBy=e8d51649330, createdName=飘飘爱, createdTime=Sun Jul 30 18:44:12 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228147, encodeId=e98322814ead, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48a92091207, createdName=1571f46522m, createdTime=Sun Jul 30 17:53:48 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228134, encodeId=1b8622813468, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Jul 30 16:25:20 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2017-10-22 stfoxst
  4. [GetPortalCommentsPageByObjectIdResponse(id=1217663, encodeId=996d121e663d8, content=学习了,涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd938151921, createdName=ms1000001061862426, createdTime=Sat May 07 16:52:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029812, encodeId=09332029812e0, content=<a href='/topic/show?id=840c651286' target=_blank style='color:#2F92EE;'>#eCTD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6512, encryptionId=840c651286, topicName=eCTD)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Aug 28 21:10:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890644, encodeId=584e189064468, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sun Oct 22 19:10:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228284, encodeId=66c622828461, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 31 06:14:14 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228154, encodeId=6e492281540e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 30 19:13:24 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228152, encodeId=2883228152e2, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2emBzjO0FtqTJ05AqrEEdRmp6tmlsLXqpzfxWdtgbbgPGWRHagoK9fLTd3IayRPgkJVIVBWtdlmnkBhOIR4cFM/0, createdBy=e8d51649330, createdName=飘飘爱, createdTime=Sun Jul 30 18:44:12 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228147, encodeId=e98322814ead, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48a92091207, createdName=1571f46522m, createdTime=Sun Jul 30 17:53:48 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228134, encodeId=1b8622813468, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Jul 30 16:25:20 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2017-07-31 189****7206

    学习了受益匪浅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1217663, encodeId=996d121e663d8, content=学习了,涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd938151921, createdName=ms1000001061862426, createdTime=Sat May 07 16:52:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029812, encodeId=09332029812e0, content=<a href='/topic/show?id=840c651286' target=_blank style='color:#2F92EE;'>#eCTD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6512, encryptionId=840c651286, topicName=eCTD)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Aug 28 21:10:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890644, encodeId=584e189064468, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sun Oct 22 19:10:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228284, encodeId=66c622828461, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 31 06:14:14 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228154, encodeId=6e492281540e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 30 19:13:24 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228152, encodeId=2883228152e2, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2emBzjO0FtqTJ05AqrEEdRmp6tmlsLXqpzfxWdtgbbgPGWRHagoK9fLTd3IayRPgkJVIVBWtdlmnkBhOIR4cFM/0, createdBy=e8d51649330, createdName=飘飘爱, createdTime=Sun Jul 30 18:44:12 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228147, encodeId=e98322814ead, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48a92091207, createdName=1571f46522m, createdTime=Sun Jul 30 17:53:48 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228134, encodeId=1b8622813468, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Jul 30 16:25:20 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2017-07-30 清风拂面

    谢谢分享,学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1217663, encodeId=996d121e663d8, content=学习了,涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd938151921, createdName=ms1000001061862426, createdTime=Sat May 07 16:52:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029812, encodeId=09332029812e0, content=<a href='/topic/show?id=840c651286' target=_blank style='color:#2F92EE;'>#eCTD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6512, encryptionId=840c651286, topicName=eCTD)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Aug 28 21:10:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890644, encodeId=584e189064468, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sun Oct 22 19:10:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228284, encodeId=66c622828461, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 31 06:14:14 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228154, encodeId=6e492281540e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 30 19:13:24 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228152, encodeId=2883228152e2, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2emBzjO0FtqTJ05AqrEEdRmp6tmlsLXqpzfxWdtgbbgPGWRHagoK9fLTd3IayRPgkJVIVBWtdlmnkBhOIR4cFM/0, createdBy=e8d51649330, createdName=飘飘爱, createdTime=Sun Jul 30 18:44:12 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228147, encodeId=e98322814ead, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48a92091207, createdName=1571f46522m, createdTime=Sun Jul 30 17:53:48 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228134, encodeId=1b8622813468, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Jul 30 16:25:20 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2017-07-30 飘飘爱

    很好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1217663, encodeId=996d121e663d8, content=学习了,涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd938151921, createdName=ms1000001061862426, createdTime=Sat May 07 16:52:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029812, encodeId=09332029812e0, content=<a href='/topic/show?id=840c651286' target=_blank style='color:#2F92EE;'>#eCTD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6512, encryptionId=840c651286, topicName=eCTD)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Aug 28 21:10:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890644, encodeId=584e189064468, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sun Oct 22 19:10:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228284, encodeId=66c622828461, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 31 06:14:14 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228154, encodeId=6e492281540e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 30 19:13:24 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228152, encodeId=2883228152e2, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2emBzjO0FtqTJ05AqrEEdRmp6tmlsLXqpzfxWdtgbbgPGWRHagoK9fLTd3IayRPgkJVIVBWtdlmnkBhOIR4cFM/0, createdBy=e8d51649330, createdName=飘飘爱, createdTime=Sun Jul 30 18:44:12 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228147, encodeId=e98322814ead, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48a92091207, createdName=1571f46522m, createdTime=Sun Jul 30 17:53:48 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228134, encodeId=1b8622813468, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Jul 30 16:25:20 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2017-07-30 1571f46522m

    学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1217663, encodeId=996d121e663d8, content=学习了,涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd938151921, createdName=ms1000001061862426, createdTime=Sat May 07 16:52:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029812, encodeId=09332029812e0, content=<a href='/topic/show?id=840c651286' target=_blank style='color:#2F92EE;'>#eCTD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6512, encryptionId=840c651286, topicName=eCTD)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Aug 28 21:10:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890644, encodeId=584e189064468, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sun Oct 22 19:10:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228284, encodeId=66c622828461, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 31 06:14:14 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228154, encodeId=6e492281540e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 30 19:13:24 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228152, encodeId=2883228152e2, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2emBzjO0FtqTJ05AqrEEdRmp6tmlsLXqpzfxWdtgbbgPGWRHagoK9fLTd3IayRPgkJVIVBWtdlmnkBhOIR4cFM/0, createdBy=e8d51649330, createdName=飘飘爱, createdTime=Sun Jul 30 18:44:12 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228147, encodeId=e98322814ead, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48a92091207, createdName=1571f46522m, createdTime=Sun Jul 30 17:53:48 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228134, encodeId=1b8622813468, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Jul 30 16:25:20 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2017-07-30 楠博One

    学习谢谢分享

    0

相关资讯

CFDA全新简讯:通过申请,成为ICH成员!

CFDA最新简讯:通过申请,成为ICH成员!

华杰鸿:CFDA成为国际药品注册标准制订者之一

ICH由监管机构及制药行业协会组成,WHO作为观察员也在其中。加入ICH后,中国国家食品药品监督管理总局将正式成为国际药品注册标准制订的重要参与者之一。

CFDA拟放宽II、III类注册检验要求,企业可以自主检验

根据械注[2017] 165号文件,总局医疗器械注册管理司将调整医疗器械检验相关工作。这次调整总体来说对企业是利好的,也是我国医疗器械注册监管迈向国际化的一步。

临床研究的春天到了?—关于CFDA 53号文

认证改为备案,将简化流程,释放大量机构、资源,比如二三线城市?

CDE与山东省药监局达成战略合作 共同提升药品审评能力

为加快推进药品审评审批制度改革,促进国家总局及省局技术审评优势互补,共同推进药品技术审评能力建设,5月26日,国家食品药品监督管理总局药审中心与山东省食品药品监督管理局签署战略合作协议。总局副局长孙咸泽出席签字仪式并讲话。

中药饮片成黑榜常客 CFDA年内曾10次点名

近日,国家食药监总局发布了《关于12批次中药饮片不合格的通告》,经中国食品药品检定研究院检验,标示为吉林省元力药业有限公司等10家企业生产的12批次中药饮片不合格。

Baidu
map
Baidu
map
Baidu
map